Whipplewood Advisors LLC Makes New $46,000 Investment in GSK plc (NYSE:GSK)

Whipplewood Advisors LLC acquired a new position in GSK plc (NYSE:GSK) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,346 shares of the pharmaceutical company’s stock, valued at approximately $46,000.

Several other hedge funds have also bought and sold shares of GSK. Allspring Global Investments Holdings LLC boosted its position in GSK by 40.7% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 11,764 shares of the pharmaceutical company’s stock worth $481,000 after purchasing an additional 3,405 shares in the last quarter. Pinnacle Associates Ltd. boosted its position in GSK by 6.2% in the 3rd quarter. Pinnacle Associates Ltd. now owns 32,921 shares of the pharmaceutical company’s stock worth $1,346,000 after purchasing an additional 1,912 shares in the last quarter. JFS Wealth Advisors LLC boosted its position in GSK by 1,429.4% in the 3rd quarter. JFS Wealth Advisors LLC now owns 29,426 shares of the pharmaceutical company’s stock worth $1,203,000 after purchasing an additional 27,502 shares in the last quarter. US Bancorp DE boosted its position in GSK by 12.2% in the 3rd quarter. US Bancorp DE now owns 236,770 shares of the pharmaceutical company’s stock worth $9,679,000 after purchasing an additional 25,781 shares in the last quarter. Finally, Lincluden Management Ltd. boosted its position in GSK by 1.3% in the 3rd quarter. Lincluden Management Ltd. now owns 66,001 shares of the pharmaceutical company’s stock worth $2,698,000 after purchasing an additional 833 shares in the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

Analysts Set New Price Targets

GSK has been the topic of a number of recent analyst reports. Jefferies Financial Group lowered GSK from a “buy” rating to a “hold” rating and decreased their target price for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 7th. Morgan Stanley initiated coverage on GSK in a research report on Wednesday, February 12th. They set an “equal weight” rating on the stock. Finally, Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Seven research analysts have rated the stock with a hold rating and four have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $43.25.

GSK Stock Up 0.8 %

NYSE GSK opened at $37.59 on Friday. The business has a fifty day moving average price of $34.99 and a 200 day moving average price of $37.28. GSK plc has a one year low of $31.72 and a one year high of $45.92. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. The company has a market cap of $77.90 billion, a P/E ratio of 23.64, a P/E/G ratio of 1.12 and a beta of 0.64.

GSK (NYSE:GSK) last posted its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. Research analysts anticipate that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be paid a $0.3932 dividend. This is an increase from GSK’s previous quarterly dividend of $0.39. This represents a $1.57 annualized dividend and a yield of 4.18%. The ex-dividend date is Friday, February 21st. GSK’s dividend payout ratio is currently 98.74%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.